H.R.6 - SUPPORT for Patients and Communities Act115th Congress (2017-2018) |
|Sponsor:||Rep. Walden, Greg [R-OR-2] (Introduced 06/13/2018)|
|Committees:||House - Energy and Commerce; Ways and Means; Judiciary|
|Latest Action:||Senate - 06/26/2018 Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 485. (All Actions)|
|Roll Call Votes:||There have been 2 roll call votes|
This bill has the status Passed House
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.6 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in House (01/03/2017)
Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act
This bill makes several changes to state Medicaid programs to address opioid and substance use disorders. Specifically, the bill:
- modifies provisions related to coverage for juvenile inmates and former foster care youth,
- establishes a demonstration project to increase provider treatment capacity for substance use disorders,
- requires the establishment of drug management programs for at-risk beneficiaries,
- establishes drug review and utilization requirements,
- extends the enhanced federal matching rate for expenditures regarding substance use disorder health home services, and
- temporarily requires coverage of medication-assisted treatment.
The bill also alters Medicare requirements to address opioid use. Specifically, the bill:
- exempts substance use disorder telehealth services from specified requirements,
- requires the initial examination for new enrollees to include an opioid use disorder screening,
- modifies provisions regarding electronic prescriptions and post-surgical pain management,
- requires prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, and
- requires coverage for services provided by certified opioid treatment programs.
The bill also addresses other opioid-related issues. Specifically, the bill:
- establishes and expands programs to support increased detection and monitoring of fentanyl and other synthetic opioids, and
- increases the maximum number of patients that health care practitioners may initially treat with medication-assisted treatment (i.e., under a buprenorphine waiver).
Additionally, the bill temporarily eliminates the enhanced federal matching rate for Medicaid expenditures regarding specified medical services provided by certain managed care organizations.